Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The newly marketed oritavancin (The Medicine…
The Vaccines Epidemiology Forecaster allows you to interactively assess assumptions about vaccine launch dates and the time taken to reach the current coverage of a particular vaccine group in a…
Abstract: Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (…
The chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML) markets are becoming increasingly crowded, with recent marketing authorizations expanding therapy options for patients. As…
Parkinson’s disease (PD) treatment is complex; the disease is heterogeneous, requiring individualized treatment and frequent adjustments to achieve symptom control. New therapies that address PD…
Pelvic pain is the main clinical manifestation associated with endometriosis, a disorder caused by endometrial tissues growing outside the uterus. Pain relievers, hormonal contraceptives, aromatase…
Market Outlook: Many cases of hospital-acquired infections and healthcare-associated illnesses are attributable to C. difficile infection (CDI). Although standard-of-care antibiotics are…
Graft versus host disease (GVHD) is a potentially life-threatening complication of allogenic hematopoietic stem-cell transplants (HSCTs). The systemic inflammatory reaction is triggered by donor T…
In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we…
Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. In this series, we track…
Non-small-cell lung cancer (NSCLC) affects thousands of individuals in Brazil and Mexico, and it is managed with premium-priced targeted agents and chemotherapy. In both countries, public coverage…
For the estimated 3 million people in the United States who have Alzheimer’s disease (AD), approved treatment is limited to five procognitive symptomatic therapies (e.g., donepezil, memantine)…
In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of PP-MS in March 2017. Although the drug’s efficacy appears more modest than in patients with relapsing forms of…
Retinitis pigmentosa (RP) is a rare genetic disorder marked by retinal degeneration, progressive vision loss, and eventual blindness. There are no approved pharmacotherapies for RP, and current…
Treatment of ulcerative colitis (UC) and Crohn’s disease (CD) within Brazil and Mexico includes many of the predominant treatments in other parts of the world such as the TNF-α inhibitors…